Van ECK Associates Corp Invests $9.14 Million in Insmed Incorporated (NASDAQ:INSM)

Van ECK Associates Corp acquired a new position in Insmed Incorporated (NASDAQ:INSM - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 127,024 shares of the biopharmaceutical company's stock, valued at approximately $9,138,000. Van ECK Associates Corp owned about 0.09% of Insmed as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of INSM. Clearbridge Investments LLC bought a new position in shares of Insmed during the 1st quarter valued at $25,242,000. Kennedy Capital Management LLC purchased a new position in shares of Insmed during the first quarter valued at approximately $267,000. Susquehanna Fundamental Investments LLC purchased a new position in shares of Insmed in the first quarter worth $4,515,000. Russell Investments Group Ltd. increased its holdings in Insmed by 15,915.2% in the 1st quarter. Russell Investments Group Ltd. now owns 22,101 shares of the biopharmaceutical company's stock worth $600,000 after acquiring an additional 21,963 shares in the last quarter. Finally, &PARTNERS bought a new stake in Insmed during the second quarter valued at about $300,000.

Insider Buying and Selling at Insmed

In related news, insider Martina M.D. Flammer sold 13,436 shares of the business's stock in a transaction on Monday, September 16th. The stock was sold at an average price of $74.92, for a total value of $1,006,625.12. Following the sale, the insider now owns 106,134 shares in the company, valued at approximately $7,951,559.28. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, insider Martina M.D. Flammer sold 13,436 shares of the company's stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $74.92, for a total transaction of $1,006,625.12. Following the completion of the transaction, the insider now directly owns 106,134 shares of the company's stock, valued at approximately $7,951,559.28. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Michael Alexander Smith sold 27,871 shares of the stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $74.35, for a total transaction of $2,072,208.85. Following the completion of the transaction, the insider now owns 67,856 shares in the company, valued at $5,045,093.60. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 78,882 shares of company stock worth $5,765,446 over the last quarter. 4.60% of the stock is currently owned by company insiders.

Insmed Price Performance

NASDAQ INSM traded down $1.02 during trading hours on Thursday, hitting $71.84. 503,533 shares of the company's stock traded hands, compared to its average volume of 2,261,684. Insmed Incorporated has a 52-week low of $21.92 and a 52-week high of $80.53. The company has a market capitalization of $12.85 billion, a PE ratio of -13.13 and a beta of 1.12. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The firm's 50-day moving average is $72.66 and its 200-day moving average is $62.45.

Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.19) by ($0.08). The company had revenue of $93.40 million for the quarter, compared to analysts' expectations of $93.36 million. During the same period in the prior year, the firm posted ($1.10) EPS. The company's revenue was up 18.1% compared to the same quarter last year. Equities analysts forecast that Insmed Incorporated will post -5.52 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have issued reports on INSM shares. HC Wainwright reaffirmed a "buy" rating and issued a $90.00 price objective on shares of Insmed in a research note on Friday, November 1st. The Goldman Sachs Group upped their target price on Insmed from $74.00 to $102.00 and gave the stock a "buy" rating in a report on Wednesday, July 10th. StockNews.com cut Insmed from a "hold" rating to a "sell" rating in a research note on Friday, August 9th. UBS Group lifted their target price on Insmed from $78.00 to $84.00 and gave the company a "buy" rating in a research note on Friday, August 9th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Insmed in a research report on Monday, September 9th. One investment analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat, Insmed presently has an average rating of "Moderate Buy" and an average target price of $83.07.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.